vimarsana.com

Page 24 - சிங்கப்பூர் பொருளாதார வளர்ச்சி பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BioNTech to set up mNRA vaccines manufacturing facility, Southeast Asia centre in Singapore

BioNTech to set up mNRA vaccines manufacturing facility, Southeast Asia centre in Singapore 11 May 2021 / 00:06 H. The BioNTech logo is seen at the company’s manufacturing site for the production of the Covid-19 vaccine is seen in Marburg, central Germany. – AFPPIX BERLIN: BioNTech plans to set up a regional centre and a factory in Singapore for its vaccines, it said on Monday, boosting its presence in Asia as a debate over patents rages and pressure grows on drugmakers to raise output of Covid-19 shots. Governments are looking to build up local vaccine production to secure access to supplies after manufacturing setbacks have slowed the rollout of Covid-19 doses in some countries.

BioNTech to produce mRNA vaccines in Singapore, its new regional headquarters

BioNTech to produce mRNA vaccines in Singapore, its new regional headquarters Toggle share menu Advertisement The manufacturing facility in Singapore could be operational as early as 2023. German biotechnology firm BioNTech, which partnered Pfizer to develop a COVID-19 vaccine using messenger RNA (mRNA) technology, will set up its regional headquarters in Singapore, along with a manufacturing facility. Brandon Tanoto with more.  2 related media assets (image or videos) available. Click to see the gallery. 10 May 2021 11:26PM) Share this content Bookmark SINGAPORE: German biotechnology firm BioNTech, which partnered Pfizer to develop a COVID-19 vaccine using messenger RNA (mRNA) technology, will set up its regional headquarters in Singapore, along with a manufacturing facility.   

BioNTech Secures Manufacturing Capacity in Asia for mRNA Vaccine and Therapeutics

Published: May 10, 2021 By Alex Keown Boris Roessler/picture alliance via Getty Images Building on the success of its mRNA research, establish its first regional hub in the Asia Pacific region. The company will open a state-of-the-art manufacturing facility to support a global supply of mRNA-based vaccines and therapeutics in Singapore. This morning, Germany-based BioNTech announced it was expanding its global footprint with the new site in Asia. The facility will provide rapid-response capabilities for future pandemic threats in Southeast Asia.  The development of the new facility will be supported by the Singapore Economic Development Board (EDB). In its announcement, BioNTech declined to provide information regarding the expected manufacturing costs.

BioNTech Plans Fully Integrated mRNA Manufacturing Facility in Singapore

BioNTech Plans Fully Integrated mRNA Manufacturing Facility in Singapore series of Covid19 vaccine vials May 10, 2021 BioNTech plans to expand its global footprint to Asia with the establishment of its regional headquarters for Southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, and is intended to serve as a rapid response production capability for Southeast Asia to address potential pandemic threats.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.